SLS Stock Jumps 3% Overnight as Regal Trial Nears Final Event; CEO Eyes Fox Appearance

SLS-5.24%
According to Stocktwits, Sellas Life Sciences stock jumped 3% overnight (July 20) as retail traders bet the Phase 3 Regal trial's final acute myeloid leukemia readout could spark Big Pharma bidding interest ahead of CEO Angelos Stergiou's Fox appearance. The Regal trial has reached 78 of the 80 events required to trigger its final analysis of galinpepimut-S (GPS) in AML patients. Stergiou announced on LinkedIn last week he would return to Fox & Friends to discuss Sellas' clinical programs and GPS, with the segment date and time still being finalized.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments